• News
  • Asia

Onward Therapeutics Raises NT$900 Million Series B

Taipei oncology company secures approximately US$28 million for clinical pipeline

11/18/2026
•Ali Abounasr El Alaoui
Back to News

Onward Therapeutics raised NT$900 million, approximately US$28 million, in a Series B financing round. The clinical-stage company develops cancer therapies for difficult-to-treat or relapsed cancers. Existing investors CDIB Capital Healthcare Ventures and Hong Kong Chlitina International backed the round.


Funding details

The round closed in two parts, with the second closing in October 2026. Before this Series B, the company had raised CHF 75.5 million, approximately US$90 million. The new funds will support clinical programs, clinical supply manufacturing, and early-stage research.

Company background

Onward Therapeutics was founded in November 2019. Its global headquarters moved from Switzerland to Taipei in October 2025, and it has teams in Switzerland and France. Dr. C. Grace Yeh serves as chairperson and CEO.

Clinical pipeline

Its portfolio includes two clinical-stage programs and two early-stage discovery programs. OT-A201 is a tetravalent bispecific antibody that has completed monotherapy dose escalation and advanced into Phase 1b. OT-C001 is an off-the-shelf natural killer cell therapy in a Phase 1 trial in France for relapsed or refractory diffuse large B-cell lymphoma.


Onward Therapeutics signed a listing advisory agreement with a securities firm. It is preparing to register on the Taipei Exchange Emerging Stock Board by the end of 2027. The company also plans to expand its team and start clinical trials in Taiwan.